Angiotensin 1-7 Cardioprotection: Mechanisms, Research, and Therapeutic Potential
Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
># Angiotensin 1-7 Cardioprotection: Mechanisms, Research, and Therapeutic Potential...
># Angiotensin 1-7 Cardioprotection: Mechanisms, Research, and Therapeutic Potential
Angiotensin-(1-7) (Ang-(1-7)) is a peptide hormone that has emerged as a key player in cardiovascular health and disease. As a component of the renin-angiotensin system (RAS), Ang-(1-7) counteracts the detrimental effects of the classical RAS axis, which is mediated by angiotensin II (Ang II). This has led to a surge of interest in its cardioprotective properties and its potential as a therapeutic agent for a variety of cardiovascular disorders. This article delves into the mechanisms of Ang-(1-7) cardioprotection, reviews the current research, and explores its therapeutic potential.
Mechanisms of Angiotensin-(1-7) Cardioprotection
Ang-(1-7) exerts its cardioprotective effects through a variety of mechanisms, primarily by activating the Mas receptor, a G protein-coupled receptor. The Ang-(1-7)/Mas axis acts as a counter-regulatory pathway to the Ang II/AT1 receptor axis, which is known to promote vasoconstriction, inflammation, and fibrosis. The key mechanisms of Ang-(1-7) cardioprotection include:
Vasodilation: Ang-(1-7) promotes the release of nitric oxide (NO) from endothelial cells, leading to vasodilation and a reduction in blood pressure.
Anti-inflammatory effects: Ang-(1-7) has been shown to reduce the production of pro-inflammatory cytokines and adhesion molecules, thereby mitigating inflammation in the cardiovascular system.
Anti-fibrotic effects: Ang-(1-7) can inhibit the proliferation of cardiac fibroblasts and the deposition of collagen, thus preventing the development of cardiac fibrosis.
Anti-hypertrophic effects: Ang-(1-7) has been shown to attenuate cardiac hypertrophy, the thickening of the heart muscle, which is a common pathological response to various cardiovascular insults.
Research on Angiotensin-(1-7) Cardioprotection
Extensive research in preclinical models has provided compelling evidence for the cardioprotective effects of Ang-(1-7). Studies in animal models of hypertension, myocardial infarction, and heart failure have consistently shown that administration of Ang-(1-7) can improve cardiac function, reduce cardiac remodeling, and increase survival. For example, a study in a rat model of myocardial infarction found that Ang-(1-7) treatment reduced infarct size and improved cardiac function. Another study in a mouse model of heart failure showed that Ang-(1-7) attenuated cardiac hypertrophy and fibrosis.
Clinical studies are also beginning to emerge, providing further support for the cardioprotective effects of Ang-(1-7) in humans. A clinical trial in patients with heart failure found that infusion of Ang-(1-7) improved endothelial function and reduced markers of inflammation. Another study in patients with hypertension showed that oral administration of an Ang-(1-7) formulation lowered blood pressure.
| Cardiovascular Condition | Cardioprotective Effects of Angiotensin-(1-7) | Supporting Evidence |
|---|---|---|
| Hypertension | Lowers blood pressure and improves endothelial function | Preclinical and clinical studies |
| Myocardial Infarction | Reduces infarct size and improves cardiac function | Preclinical studies |
| Heart Failure | Attenuates cardiac hypertrophy and fibrosis | Preclinical and clinical studies |
| Atherosclerosis | Reduces inflammation and plaque formation | Preclinical studies |
Therapeutic Potential of Angiotensin-(1-7)
The cardioprotective properties of Ang-(1-7) make it a highly attractive therapeutic target for a variety of cardiovascular diseases. The development of drugs that can enhance the activity of the Ang-(1-7)/Mas axis is a major focus of current research. Several strategies are being pursued, including:
Oral formulations of Ang-(1-7): The development of oral formulations of Ang-(1-7) would provide a convenient and non-invasive way to administer the peptide.
Mas receptor agonists: The development of small molecule agonists that can activate the Mas receptor would provide an alternative to peptide-based therapies.
ACE2 activators: Since Ang-(1-7) is produced from Ang II by the enzyme angiotensin-converting enzyme 2 (ACE2), drugs that can activate ACE2 could increase the endogenous production of Ang-(1-7).
Key Takeaways
Angiotensin-(1-7) is a cardioprotective peptide that counteracts the detrimental effects of the classical renin-angiotensin system.
It exerts its cardioprotective effects through vasodilation, anti-inflammatory, anti-fibrotic, and anti-hypertrophic mechanisms.
Research in preclinical and clinical studies has provided strong evidence for the cardioprotective effects of Ang-(1-7).
The development of drugs that can enhance the activity of the Ang-(1-7)/Mas axis is a promising therapeutic strategy for cardiovascular diseases.
References
Medical Disclaimer: The information provided in this article is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional before making any decisions about your health or treatment.
---